Record Second Quarter Pro Forma Revenue(1)(2)of $165.4 Million and Record Second Quarter Managed Revenue(1)of $121.4 Million;
Record First Half Managed Revenue(1) of $226.4 Million;
Record Adjusted EBITDA(1) of $28.0 Million as Operations Across 17 States Continue to Scale;
Completed Closing of the Grassroots Acquisition Expanding Presence to 23 States
WAKEFIELD, Mass., Aug. 17, 2020 /PRNewswire/ — Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading vertically integrated cannabis operator in the U.S., today reported its financial and operating results for the second quarter ended June 30, 2020. All financial information is provided in U.S. dollars unless otherwise indicated.
Q2 2020 Financial Highlights (Unaudited)
|($ thousands, except per share amounts)||Q2 2020||Q1 2020|| % qoq|
|Q2 2019|| % yoy|
|Gross profit before impact of biological assets||$60,636||$52,483||16%||$26,020||133%|
|Gross profit on cannabis sales(1)||$42,735||$33,042||29%||$15,257||180%|
|Gross margin on cannabis sales(1)||43%||43%||40%|
|Net income (loss) attributable to Curaleaf Holdings Inc.||($2,029)||($15,089)||($24,541)|
|Net income (loss) per share – basic and diluted||($0.00)||($0.03)||(0.05)|
|(1)||See “Non-IFRS Financial and Performance Measures” below for more information regarding Curaleaf’s use of Non-IFRS financial measures and other reconciliations.|
|(2)||Pro Forma Revenue includes the revenue from closed acquisitions of Arrow Alternative Care (“Arrow”) and GR Companies, Inc. (“Grassroots”) as if they occurred on April 1, 2020.|
Second Quarter Highlights
- Record managed revenue of $121.4 million, which grew 120% year-over-year and 16% sequentially, despite estimated $25.6 million revenue related impact from COVID-19 largely in Nevada and Massachusetts
- Record total revenue of $117.5 million, which grew 142% year-over-year and 22% sequentially
- Record Adjusted EBITDA of $28.0 million, which grew more than five times 2019 levels and 40% sequentially
- Generated cash flow from operations of $23.4 million
- Select launched into 2 new states
- Completed acquisition of Arrow in Connecticut
- Completed acquisition of Maine Remedy assets that were previously managed
Post Second Quarter Highlights
- Completed acquisition of Grassroots creating the world’s largest cannabis Company
- Completed acquisition of Curaleaf NJ, Inc. and Maine Organic Therapy assets that were previously managed
- Closed acquisition of Blue Kudu enabling further roll-out of Select products in Colorado
- Select launched into 4 new states; now available in 12 states
- Completed a private placement of approximately $24.5 million in net proceeds
- Raised approximately $42.0 million in net proceeds related to sale/leaseback transactions
Joseph Lusardi, Chief Executive Officer of Curaleaf stated “Curaleaf, once again, delivered record quarterly results highlighted by managed revenues exceeding our outlook, as well as, a 40% sequential improvement in Adjusted EBITDA. The outstanding results come despite headwinds related to temporary COVID-19 related closures and restrictions in Massachusetts and Nevada. After quarter end, we successfully completed the transformative acquisition of Grassroots, expanding our presence into 6 new states, including the high-growth Illinois and Pennsylvania markets. The closing of Grassroots affirms our position as the world’s largest cannabis company when measured by both revenue and operating presence. Overall, Curaleaf remains well positioned for continued growth in the second half of 2020. This growth will be driven by organic initiatives, the integrations of the Select and Grassroots businesses, as well as, the closing of multiple strategic tuck-in acquisitions across a number of key states.”
Mike Carlotti, Chief Financial Officer of Curaleaf, added “Our top-line growth drove record adjusted EBITDA and an improved adjusted EBITDA margin. The strength of our balance sheet has allowed us to invest in our base business and opportunistically pursue additional strategic acquisitions. Looking forward, we anticipate a continued rise in managed revenue and adjusted EBITDA leading to strong sequential growth in the third quarter and second half of 2020 driven by organic growth, continued investment in key states, as well as, the integration of Select, Grassroots, Arrow and BlueKudu into our portfolio. Finally, we continue to make progress in converting and consolidating our managed entities in Maine, New Jersey and Massachusetts. As of today, we have consolidated all of our managed entities except for ATG which we expect to consolidate in the third quarter.”
Financial Results for the Second Quarter Ended June 30, 2020
Managed Revenue for the second quarter of 2020 was a record $121.4 million, an increase of 120% compared to $55.1 million in the second quarter of 2019. Managed Revenue for the second quarter increased 16% sequentially.
Total Revenue for the second quarter of 2020 was a record $117.5 million, an increase of 142% compared to $48.5 million in the second quarter of 2019. Total Revenue for the second quarter of 2020 increased 22% sequentially.
Retail revenue increased by 112% to $66.3 million during second the quarter of 2020, compared to $31.3 million in the second quarter of 2019. Growth in retail revenue was primarily due to organic growth and new store openings in Florida, Massachusetts and New York, impact of the Select acquisition, as well as, the acquisitions of three dispensaries in Arizona, two dispensaries in Nevada and from Maryland due to the addition of the HMS/MI businesses and Elevate Takoma, offset partially by the unforeseen negative impact of COVID-19 in Massachusetts and Nevada.
Wholesale revenue increased by 422% to $33.3 million during the second quarter of 2020, compared to $6.4 million in the second quarter of 2019. Growth in wholesale revenue was due primarily to the addition of Select.
Management fee income increased by 66% to $17.9 million during the second quarter of 2020, compared to $10.8 million in the second quarter of 2019. Growth in management fee income was due primarily to growth in New Jersey and management fees generated from Alternative Therapies Group (“ATG”) in Massachusetts.
Gross profit before impact of biological assets for the second quarter of 2020 was $60.6 million, compared to $26.0 million for the second quarter of 2019. The increase was primarily due to the continued improvement in the operating capacity and efficiency of the Company’s cultivation and processing facilities.
Gross profit on cannabis sales was $42.7 million for the second quarter of 2020, resulting in a 43% margin, compared to $15.3 million in the second quarter of 2019. The increase was primarily due to the continued improvement in the operating capacity and efficiency of the Company’s cultivation and processing facilities.
Adjusted EBITDA was a record $28.0 million for the second quarter of 2020, compared to $4.4 million for the second quarter of 2019.
Net loss for the second quarter of 2020 was $2.0 million, compared to a net loss of $24.5 million in the second quarter of 2019. The increase was primarily driven by a $19.2 million increase in the fair value of biological assets and a $1.1 million decrease in one-time charges. These benefits were partially offset by a $9.5 million increase in depreciation and amortization and a $0.3 million increase in share-based compensation, both of which are non-cash, a $5.3 million increase in income tax expense, and a $7.0 million increase in net interest expense.
Balance Sheet and Liquidity
As of June 30, 2020, we had $122.8 million of cash, $283.3 million of outstanding debt net of unamortized debt discounts and 533.2 million fully diluted shares outstanding.
Conference Call and Webcast Information
Curaleaf will host a conference call and audio webcast today at 5:00 pm ET to answer questions about the Company’s operational and financial highlights. The dial-in numbers for the conference call are +1-888-317-6003 (U.S.), +1-866-284-3684 (Canada) or +1-412-317-6061 (Int’l) Passcode: 0446838. Please dial-in 10 to 15 minutes prior to the start time of the conference call and an operator will register your name and organization.
The conference call will also be available via webcast, which can be accessed through the Investor Relations section of Curaleaf’s website, https://ir.curaleaf.com/events.
For interested individuals unable to join the conference call, a dial-in replay of the call will be available until August 24, 2020 at 11:59 pm ET and can be accessed by dialing +1-877-344-7529 (U.S.), +1-855-669-9658 (Canada) or +1-412-317-0088 (International) and entering replay pin number: 10146052. The online archive of the webcast will be available on https://ir.curaleaf.com/events for 90 days following the call.
Non-IFRS Financial and Performance Measures
In this press release Curaleaf refers to certain non-IFRS financial measures such as “Pro Forma Revenue”, “Managed Revenue”, “Gross Profit on Cannabis Sales” and “Adjusted EBITDA”. These measures do not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other issuers. Curaleaf defines “Managed Revenue” as total revenue plus revenue from entities for which the Company has a management contract but does not consolidate the financial results based on IFRS 10 – Consolidated Financial Statements. Curaleaf defines “Pro Forma Revenue” as “Managed Revenue” plus revenue from operations of pending and closed acquisitions as if such acquisitions occurred on April 1, 2020. The Company defines “Gross Profit on Cannabis Sales” as retail and wholesale revenues less cost of goods sold. “Adjusted EBITDA” is defined by Curaleaf as earnings before interest, taxes, depreciation and amortization less share-based compensation expense and one-time charges related to business development, acquisition, financing and reorganization costs. Curaleaf considers these measures to be an important indicator of the financial strength and performance of our business. We believe the adjusted results presented provide relevant and useful information for investors because they clarify our actual operating performance, make it easier to compare our results with those of other companies and allow investors to review performance in the same way as our management. Since these measures are not calculated in accordance with IFRS, they should not be considered in isolation of, or as a substitute for, our reported results as indicators of our performance, and they may not be comparable to similarly named measures from other companies. The following tables provide a reconciliation of each of the non-IFRS measures to its closest IFRS measure.
|Q2 2020||Q1 2020||Q2 2019|
|Management fee income||17,901||19,441||10,763|
|Revenue from managed entities, net of MSA fees||3,922||8,526||6,611|
|Gross Profit on Cannabis Sales|
|Q2 2020||Q1 2020||Q2 2019|
|Retail and wholesale revenues||$||99,579||$||77,055||$||37,726|
|Cost of goods sold||56,844||44,013||22,469|
|Gross profit on cannabis sales||$||42,735||$||33,042||$||15,257|
|Q2 2020||Q1 2020||Q2 2019|
|Net income (loss)||$||(1,836)||$||(15,452)||$||(24,435)|
|Interest expense, net||9,916||9,804||2,895|
|Income tax recovery (expense)||13,534||13,249||8,192|
|Depreciation and amortization (1)||17,869||14,906||8,338|
|Other (income) expense||77||(2,608)||1,047|
|Change in fair value of biological assets||(20,591)||(15,556)||(1,392)|
|One time charges||4,192||11,162||5,278|
|(1)||Depreciation and amortization expense in Q2 2020, Q1 2020 and Q4 2019 include amounts charged to cost of goods sold on the statement of profits and losses. Prior period Q2 2019 has been adjusted to reflect the current period calculation of Adjusted EBITDA.|
About Curaleaf Holdings
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf”) is the leading vertically integrated U.S. multi-state cannabis operator with a mission to improve lives by providing clarity around cannabis and confidence around consumption. As a high-growth cannabis company known for quality, expertise and reliability, the company and its brands, including Curaleaf and Select, provide industry-leading service, product selection and accessibility across the medical and adult-use markets. Curaleaf currently operates in 23 states with 87 dispensaries, 22 cultivation sites and over 30 processing sites, and employs over 3,000 team members across the United States. Curaleaf is listed on the Canadian Securities Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information please visit www.curaleaf.com.
|Condensed Interim Consolidated Statements of Financial Position (Unaudited)|
|June 30,||December 31,|
|Assets held for sale||35,050||—|
|Prepaid expenses and other current assets||7,342||6,479|
|Total current assets||340,140||149,531|
|Deferred tax asset||2,687||2,628|
|Property, plant and equipment, net||179,687||129,812|
|Intangible assets, net||404,110||185,635|
|Liabilities and Shareholders’ Equity|
|Income tax payable||40,308||15,114|
|Current portion of lease liability||13,415||11,835|
|Current portion of notes payable||6,290||17,000|
|Current contingent consideration liability||9,700||—|
|Liabilities held for sale||3,612||—|
|Other current liabilities||337||31,549|
|Total current liabilities||129,547||106,256|
|Deferred tax liability||85,587||22,642|
|Non-controlling interest redemption liability||2,694||2,694|
|Contingent consideration liability||81,662||32,616|
|Total Curaleaf Holdings, Inc. shareholders’ equity||681,437||408,762|
|Redeemable non-controlling interest||(2,694)||(2,694)|
|Total shareholders’ equity||677,661||403,446|
|Total liabilities and shareholders’ equity||$||1,332,578||$||736,926|
|Condensed Interim Consolidated Statements of Profits and Losses (Unaudited)|
|($ thousands, except for share and per share amounts)|
|Three Months Ended||Six Months Ended|
|June, 30||June, 30|
|Retail and wholesale revenues||$||99,579||$||37,726||$||176,635||$||65,494|
|Management fee income||17,901||10,763||37,342||18,246|
|Cost of goods sold||56,844||22,469||100,856||39,614|
|Gross profit before impact of biological assets||60,636||26,020||113,121||44,126|
|Realized fair value amounts included in inventory sold||(22,423)||(15,478)||(43,613)||(25,833)|
|Unrealized fair value gain on growth of biological assets||43,014||16,870||79,761||29,471|
|Selling, general and administrative||40,466||28,029||86,324||51,298|
|Depreciation and amortization||14,237||7,195||26,924||12,091|
|Total operating expenses||59,536||39,713||122,582||69,659|
|Income (Loss) from operations||21,691||(12,301)||26,687||(21,895)|
|Other income (expense):|
|Interest expense related to lease liabilities||(2,132)||(1,348)||(4,290)||(2,315)|
|Other income (expense)||(77)||(1,047)||2,529||(1,073)|
|Total other income (expense), net||(9,993)||(3,942)||(17,191)||(6,616)|
|Income (Loss) before provision for income taxes||11,698||(16,243)||9,496||(28,511)|
|Income tax benefit (expense)||(13,534)||(8,192)||(26,783)||(6,753)|
|Net loss and comprehensive loss||(1,836)||(24,435)||(17,287)||(35,264)|
|Less: Net income (loss) attributable to non-controlling interest||193||106||(170)||(513)|
|Net loss attributable to Curaleaf Holdings, Inc.||$||(2,029)||$||(24,541)||$||(17,117)||$||(34,751)|
|Loss per share attributable to Curaleaf Holdings, Inc. – basic and diluted||$||(0.00)||$||(0.05)||$||(0.03)||$||(0.08)|
|Weighted average common shares outstanding – basic and diluted||533,192,806||461,313,741||520,446,921||459,499,816|